Navigation Links
Sonus Pharmaceuticals and OncoGenex Technologies to Merge
Date:5/28/2008

rtunity for shareholders."

"We were attracted by the immediate value and the potential future value this transaction creates for Sonus and OncoGenex shareholders," said Mr. Cormack. "Our companies are built around very similar approaches to developing oncology products that provide better therapeutic alternatives for cancer patients. This transaction provides an exciting opportunity for the stockholders of both companies to realize the full value of each company's assets."

The combined company will have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. In addition to OGX-011, the pipeline includes two product candidates in Phase 1, and one additional product candidate that the company anticipates will move into Phase 1 clinical development within 18 months. Details on the specific products follow:

- OGX-011, also known as custirsen sodium, inhibits the production of

clusterin, a protein that is associated with treatment resistance in

a number of solid tumors, including prostate, breast, non-small cell

lung, ovarian, and bladder cancers. It has potential applicability as

a therapeutic in a broad number of cancers at different stages and

can potentially be used in combination with a variety of commonly

used cancer treatments, including chemotherapy, radiation therapy,

and hormone ablation therapy. Preliminary data in a Phase 2 clinical

trial evaluating OGX-011 in combination with second-line chemotherapy

in patients with hormone refractory prostate cancer has shown that

retreatment with docetaxel in combination with OGX-011 may reverse

docetaxel resistance and improve survival. OGX-011 is planned to

enter randomized clinical trials in patients with hormone refractory

prostate cancer that will support a N
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
2. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
3. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
4. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
5. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
6. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
7. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
8. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. Transdel Pharmaceuticals Closes $4 Million Financing
11. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 -- A novel combination of microscopy ... of Energy,s Oak Ridge National Laboratory an unprecedented look ... unusual physical and electrochemical properties. , The research ... affects the surface of a perovskite manganite, a complex ... new avenue to understand surface behavior could benefit researchers ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... Yung-Eun Sung has announced that they have developed ... which can be applied as high performance electrodes ... is both a group leader at the Center ... (IBS) and a professor at the Seoul National ... regards to the development of relative simplicity, scalablity, ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... and scale of EDS services allow Bristol-Myers Squibb to ... focus on core biopharmaceutical business, ... million information technology (IT) services contract that,calls for EDS to ... scope and scale will allow the company to,improve productivity so ...
... SpectraScience, Inc. (OTC,Bulletin Board: SCIE) announced today that ... of Finance and Chief Financial Officer., Jim Hitchin ... many years of,experience in public medical device, manufacturing and ... 25 years ago. With a graduate,degree in accounting, he ...
... Dec. 10 iCAD, Inc. (Nasdaq:,ICAD), an industry-leading ... identification of cancer, today announced that two,U.S. Patents, ... granted,to the Company by the United States Patent ... our on-going commitment to broadening,and protecting our intellectual ...
Cached Biology Technology:EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 2EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 3Jim Dorst Joins SpectraScience as CFO 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 3
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... 45% on average over a 35 year period in ... the impact of humans on declining animal numbers. This ... as insects, spiders, crustaceans, slugs and worms bring to ... crops, decomposition for nutrient cycling, water filtration and human ... and led by UCL, Stanford and UCSB, focused on ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... working in College of Life Science, Zhejiang University, has ... CpG island has a parental differentially methylated region (DMR). ... imprinting exists in lower vertebrates and genomic imprinting should ... mammals. The study is reported in volume 54 (Issue ...
... A team of University of Oregon biologists, using fruit ... specific cells, opening a new window on how gene ... While DNA (deoxyribonucleic acid) provides an identical genetic blueprint ... that turn protein molecules on and off in different ...
... is the latest American Chemical Society (ACS) Weekly PressPac ... from ACS, 34 peer-reviewed journals and Chemical & Engineering ... Society as the source for this information. ... melamine-adulterated food , Journal of Agricultural and Food ...
Cached Biology News:The evolutionary foundation of genomic imprinting in lower vertebrates 2New tool isolates RNA within specific cells 2American Chemical Society's Weekly PressPac -- May 13, 2009 2American Chemical Society's Weekly PressPac -- May 13, 2009 3American Chemical Society's Weekly PressPac -- May 13, 2009 4American Chemical Society's Weekly PressPac -- May 13, 2009 5American Chemical Society's Weekly PressPac -- May 13, 2009 6American Chemical Society's Weekly PressPac -- May 13, 2009 7American Chemical Society's Weekly PressPac -- May 13, 2009 8American Chemical Society's Weekly PressPac -- May 13, 2009 9American Chemical Society's Weekly PressPac -- May 13, 2009 10
hnRNP U (H-94)...
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
... causing shortages in your laboratory or fellow ... unwanted distractions, problems and delays. ... hard work and endeavour! Bring us your ... market it internationally. We work under ISO ...
... from vaccinia virus is a type I ... negative superhelical turns (also called right- and ... product of the reaction is a covalently ... negative superhelical turns. DNA Topoisomerase I does ...
Biology Products: